Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Latest Information Update: 27 Jan 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms NIRT 2-HNC
- 11 Jan 2022 Planned End Date changed from 1 Jan 2030 to 11 Jan 2031.
- 11 Jan 2022 Planned primary completion date changed from 1 Jan 2026 to 11 Jan 2027.
- 11 Jan 2022 Status changed from not yet recruiting to recruiting.